Quick Answer
PLIANT THERAPEUTICS, INC. reported Cash And Cash Equivalents At Carrying Value of $45.45 million for the year ending 2025.
- PLIANT THERAPEUTICS, INC. showed a decrease of -36.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from PLIANT THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $178.46 million | Q3 2020: $55.22 million | Q1 2021: $50.82 million | Q2 2021: $35.19 million | Q3 2021: $45.23 million | Q1 2022: $32.55 million | Q2 2022: $25.07 million | Q3 2022: $44.62 million | Q1 2023: $102.53 million | Q2 2023: $54.95 million | Q3 2023: $57.68 million | Q1 2024: $114.30 million | Q2 2024: $80.39 million | Q3 2024: $79.62 million | Q1 2025: $91.94 million | Q2 2025: $86.82 million | Q3 2025: $93.73 million.
- Over the full 7 years of available data (2019 to 2025), PLIANT THERAPEUTICS, INC.'s Cash And Cash Equivalents At Carrying Value has declined by 47.0%.
- Historical annual values: Fiscal year 2025: $45.45 million | Fiscal year 2024: $71.19 million | Fiscal year 2023: $63.23 million | Fiscal year 2022: $33.69 million | Fiscal year 2021: $51.67 million | Fiscal year 2020: $50.88 million | Fiscal year 2019: $85.81 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: